Drugs for West Nile Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 29)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Maraviroc |
Approved, Investigational |
Phase 4 |
|
376348-65-1 |
3002977 |
Synonyms:
376348-65-1
4,4-difluoro-N-((1S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
674782-29-7
AC1MHEFQ
AC-558
Celsentri
Celsentri(TM)
CHEBI:537583
CHEMBL1201187
CHEMBL256907
CID3002977
DB04835
exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide
|
LS-182818
maraviroc
Maraviroc
Maraviroc [USAN]
Maravirocum
MVC
Pfizer brand OF maraviroc
PRO 140 & Maraviroc
PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
Selzentry
Selzentry(TM)
UK 427857
UK-427,857
UK-427,857 maraviroc (MVC)
UK-427857
UNII-MD6P741W8A
|
|
2 |
|
Vaccines |
|
Phase 4 |
|
|
|
3 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
4 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
5 |
|
Anti-HIV Agents |
|
Phase 4 |
|
|
|
6 |
|
Anti-Retroviral Agents |
|
Phase 4 |
|
|
|
7 |
|
Hydroxychloroquine |
Approved |
Phase 2, Phase 3 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
Axemal
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
Dolquine
EINECS 204-249-8
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
|
Hidroxicloroquina
Hidroxicloroquina [inn-spanish]
Hidroxicloroquina [INN-Spanish]
HMS502P04
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [dcit]
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Plaquenil
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
8 |
|
Nitazoxanide |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
55981-09-4 |
41684 |
Synonyms:
(2-((5-Nitro-2-thiazolyl)carbamoyl)phenyl)acetat
[2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate
2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide
2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate
2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide
55981-09-4
AC-1302
AC1L26A1
AC1Q5NVY
Alinia
Alinia (TN)
AZT + Nitazoxanide
azt+ nitazoxanide
BRN 1225475
C12H9N3O5S
CHEMBL1401
CID41684
Colufase
Columbia brand 1 OF nitazoxanide
Columbia brand 2 OF nitazoxanide
Columbia brand 3 OF nitazoxanide
CPD000466367
Cryptaz
D02486
Daxon
Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide
DB00507
EINECS 259-931-8
FT-0082459
Heliton
HMS2051L04
I14-6011
LS-144176
MLS000759492
MLS001424074
MolPort-002-042-244
|
N-(5-Nitro-2-thiazolyl)salicylamide acetate (ester)
N-(5-Nitrothiazol-2-yl)salicylamide acetate ester
NCGC00090774-01
NCI60_034935
NCIMech_000843
Nitaxozanid
Nitaxozanide
Nitazoxanid
Nitazoxanida
Nitazoxanida [INN-Spanish]
Nitazoxanide
NITAZOXANIDE
Nitazoxanide (USAN/INN)
Nitazoxanide [USAN:INN]
Nitazoxanidum
Nitazoxanidum [INN-Latin]
NSC 697855
NSC697855
NTZ
o-(N-(5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate
Oprea1_263587
Phavic-1
Romark brand 1 OF nitazoxanide
Romark brand 2 OF nitazoxanide
S1627_Selleck
Salicylamide, N-(5-nitro-2-thiazolyl)- acetate (ester)
Salicylamide, N-(5-nitro-2-thiazolyl)-, acetate (ester)
SAM001246708
SBB068315
SMR000466367
STK395664
Taenitaz
Tizoxanide glucuronide
UNII-SOA12P041N
ZINC03956788
|
|
9 |
|
Ivermectin |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
70288-86-7 |
6474909 |
Synonyms:
(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
71827-03-7
AB00513813
AC1MJ4GR
AC1N7O27
BPBio1_000322
BRD-K24652731-001-02-7
BSPBio_000292
CHEMBL341047
CID11957587
CID4330618
CID6321424
CID6419971
CID6427057
EU-0100693
FT-0082656
HMS1568O14
HMS2089M09
I 8898
I8898_SIGMA
|
Ivermectin
IVERMECTIN
Ivermectina
Ivermectine
Ivermectinum
Lopac0_000693
MK-933
MLS001333247
MLS001333248
MLS002153248
MolPort-006-394-715
NCGC00094047-01
NCGC00094047-02
NCGC00094047-03
Prestwick_516
Prestwick2_000156
Prestwick3_000156
S1351_Selleck
SMR000857211
|
|
10 |
|
Antiprotozoal Agents |
|
Phase 2, Phase 3 |
|
|
|
11 |
|
Antiparasitic Agents |
|
Phase 2, Phase 3 |
|
|
|
12 |
|
Antimalarials |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
Antirheumatic Agents |
|
Phase 2, Phase 3 |
|
|
|
14 |
|
Ribavirin |
Approved |
Phase 2 |
|
36791-04-5 |
37542 |
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
C-Virin
D00423
DB00811
Dermatech brand OF ribavirin
DivK1c_000782
DRG-0028
Drug: Ribavirin
Essex brand OF ribavirin
EU-0101063
FT-0082885
Grossman brand OF ribavirin
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN brand OF ribavirin
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
Lopac0_001063
LS-1241
Merck brand OF ribavirin
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
|
NINDS_000782
NSC 163039
NSC163039
Pfizer brand OF ribavirin
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
Ravanex
RBV
Rebetol
Rebetol (TN)
Rebetron
Rebretron
RG-964
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
RIBAV
ribavirin
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin [USAN:INN]
Ribavirin Capsules
Ribavirin merck brand
Ribavirin Triphosphate
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirin-TP
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
RTC
RTCA
RTP
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
Spectrum_001826
SPECTRUM1503938
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
SR-01000076112-3
Three rivers pharmaceuticals brand OF ribavirin
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
|
|
15 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
83869-56-1, 123774-72-1 |
|
Synonyms:
123774-72-1
D05803
Leukine
Leukine (TN)
Recombinant human granulocyte-macrophage colony stimulating factor
rGM-CSF
|
rHu GM-CSF
Sargramostim
Sargramostim (genetical recombination)
Sargramostim (genetical recombination) (JAN)
Sargramostim (USAN/INN)
|
|
16 |
|
Glycine |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
56-40-6 |
750 |
Synonyms:
(1-13c)glycinato
(15N)Glycine
15527_RIEDEL
15527_SIAL
15743-44-9 (mono-potassium salt)
17829-66-2 (cobalt salt)
18875-39-3
2,2-dialkylglycines
2311-65-1
25718-94-9
29728-27-6 (monoammonium salt)
2-Aminoacetate
2-Aminoacetic acid
32817-15-5 (copper salt)
33226_RIEDEL
33226_SIAL
33242-26-1 (calcium salt)
35947-07-0 (calcium salt (2:1))
410225_SIAL
50046_FLUKA
50046_SIGMA
513-29-1 (sulfate (3:1))
52955-63-2
56-40-6
57678-19-0
6000-43-7 (hydrochloride)
6000-44-8 (mono-hydrochloride salt)
63183-41-5 (hydrochloride hydrogen carbonate)
71295-98-2 (phosphate (1:1))
7490-95-1 (hydrochloride (2:1)
7490-95-1 (hydrochloride (2:1))
7575-55-5
848646-45-7
87867-94-5
AB1002628
AB-131/40217813
AC1L19XW
AC1Q28JW
AC1Q53O0
Acid, aminoacetic
Acide aminoacetique
Acide aminoacetique [INN-French]
Acido aminoacetico
Acido aminoacetico [INN-Spanish]
Acidum aminoaceticum
Acidum aminoaceticum [INN-Latin]
Aciport
AI3-04085
AKOS000119626
amino-Acetate
Aminoacetate
aminoacetic acid
amino-Acetic acid
Aminoacetic acid
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER
Aminoazijnzuur
Aminoessigsaeure
Aminoessigsäure
Aminoethanoate
Aminoethanoic acid
Amitone
an alpha amino acid ester
AR-1A0345
AR-1A0532
B72BA06C-60E9-4A83-A24A-A2D7F465BB65
Biomol-NT_000195
bmse000089
BPBio1_001222
C00037
Calcium salt glycine
CCRIS 5915
CHEBI:15428
CHEBI:15705
CHEBI:16228
CHEMBL773
CID750
Cobalt salt glycine
Copper salt glycine
Corilin
CPD-8569
D00011
DB00145
EINECS 200-272-2
FEMA No. 3287
FT-0083159
G
G0099
G0317
G5417_SIGMA
G5523_SIGMA
|
G7126_SIGMA
G7403_SIGMA
G8790_SIGMA
G8898_SIGMA
Glicina
Glicina [INN-Spanish]
Glicoamin
gly
Gly
GLY (IUPAC abbrev)
Glycin
glycine
Glycine
Glycine (JP15/USP)
Glycine [INN]
GLYCINE 1.5% IN PLASTIC CONTAINER
Glycine carbonate (1:1), monosodium salt
Glycine carbonate (2:1), monolithium salt
Glycine carbonate (2:1), monopotassium salt
Glycine carbonate (2:1), monosodium salt
Glycine hydrochloride
Glycine hydrochloride (2:1)
Glycine iron sulphate (1:1)
Glycine phosphate
Glycine phosphate (1:1)
Glycine sulfate (3:1)
GLYCINE, ACS
Glycine, calcium salt
Glycine, calcium salt (2:1)
Glycine, cobalt salt
Glycine, copper salt
Glycine, homopolymer (VAN)
Glycine, labeled with carbon-14
Glycine, monoammonium salt
Glycine, monopotasssium salt
Glycine, monosodium salt
Glycine, non-medical
Glycine, sodium hydrogen carbonate
Glycine-UL-14C hydrochloride
Glycinum
Glycinum [INN-Latin]
Glycocoll
Glycolixir
Glycosthene
Glykokoll
Glyzin
Gyn-hydralin
H2N-CH2-COOH
Hampshire glycine
Hgly
H-Gly-OH
HSDB 495
Hydrochloride, glycine
InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5
KST-1A2919
KST-1A8102
L001246
L-alpha-amino acids
Leimzucker
L-Glycine
LS-218
MolPort-000-871-607
Monoammonium salt glycine
Monopotasssium salt glycine
Monosodium salt glycine
NCGC00024503-01
NCGC00024503-02
nchem.554-comp2
nchembio.121-comp9
nchembio.145-comp33
nchembio.198-comp12
NChemBio.2007.13-comp1
nchembio.265-comp9
nchembio.266-comp30
NSC 25936
NSC25936
P8791_SIGMA
Padil
Phosphate, glycine
polyglycine
Polyglycine II
S04-0135
Salt glycine, monoammonium
Salt glycine, monosodium
Sucre de gelatine
Tocris-0219
UNII-TE7660XO1C
W328707_ALDRICH
WLN: Z1VQ
|
|
17 |
|
Molgramostim |
Investigational |
Phase 2 |
|
99283-10-0 |
|
18 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
19 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
20 |
|
Rho(D) Immune Globulin |
|
Phase 2 |
|
|
|
21 |
|
gamma-Globulins |
|
Phase 2 |
|
|
|
22 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
23 |
|
Immunoglobulin G |
|
Phase 2 |
|
|
|
24 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
25 |
|
Antibodies |
|
Phase 2 |
|
|
|
26 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
27 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
28 |
|
Aluminum sulfate |
Approved |
Phase 1 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
29 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 1 |
|
21645-51-2 |
|
Synonyms:
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
|
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
Interventional clinical trials:
(show all 41)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study on Maraviroc, an Oral ART CCR5 Inhibitor, on the Intensification of Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens |
Terminated |
NCT01049204 |
Phase 4 |
Maraviroc;placebo |
2 |
Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial |
Recruiting |
NCT04391127 |
Phase 3 |
Hydroxychloroquine;Ivermectin;Placebo |
3 |
Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial |
Not yet recruiting |
NCT04387760 |
Phase 2, Phase 3 |
Hydroxychloroquine;Favipiravir |
4 |
Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope |
Not yet recruiting |
NCT04360356 |
Phase 2, Phase 3 |
|
5 |
Treatment of Japanese Encephalitis - a Double Blind Placebo Controlled Trial |
Unknown status |
NCT00216268 |
Phase 2 |
Ribavirin |
6 |
Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults. |
Completed |
NCT00746798 |
Phase 2 |
|
7 |
Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults |
Completed |
NCT00442169 |
Phase 2 |
|
8 |
A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV) |
Completed |
NCT00069316 |
Phase 2 |
Omr-IgG-am |
9 |
A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (OMR-IGG-AM) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis |
Completed |
NCT00068055 |
Phase 1, Phase 2 |
Omr-lgG-am;Polygam® S/D;Placebo |
10 |
A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal |
Completed |
NCT01856205 |
Phase 2 |
Intravenous immunoglobulin [ImmunoRelâ„¢ (batch 20081217)] |
11 |
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT) |
Completed |
NCT00711035 |
Phase 1, Phase 2 |
|
12 |
Phase 2, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MGAWN1 in Subjects With Laboratory-documented West Nile Fever or Suspected Central Nervous System Infection Due to West Nile Virus |
Terminated |
NCT00927953 |
Phase 2 |
|
13 |
Phase II Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant |
Terminated |
NCT01174082 |
Phase 2 |
GM-CSF |
14 |
Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3'delta30 Chimeric Virus Vaccine (WN/DEN4delta30), a Live Attenuated Vaccine for West Nile Encephalitis |
Completed |
NCT00537147 |
Phase 1 |
|
15 |
Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis |
Completed |
NCT00094718 |
Phase 1 |
|
16 |
A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects |
Completed |
NCT00300417 |
Phase 1 |
VRC-WNVDNA020-00-VP |
17 |
A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00 VP, in Healthy Adult Volunteers |
Completed |
NCT00106769 |
Phase 1 |
VRC-WNVDNA017-00-VP |
18 |
Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3´Î”30 Chimeric Virus Vaccine (WN/DEN4Δ30), a Live Attenuated Vaccine for West Nile Encephalitis, in Flavivirus-naïve Adults 50-65 Years of Age |
Completed |
NCT02186626 |
Phase 1 |
|
19 |
A Double Blind, Randomized, Placebo-Controlled, Phase I Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults |
Completed |
NCT02337868 |
Phase 1 |
|
20 |
Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults |
Completed |
NCT00707642 |
Phase 1 |
|
21 |
Pharmacokinetic Study of AVI-4020 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration |
Completed |
NCT00387283 |
Phase 1 |
AVI-4020 Injection |
22 |
A Phase 1, Randomized, Double-Blind, Dose-Escalation Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of MGAWN1, a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus, in Healthy Adults |
Completed |
NCT00515385 |
Phase 1 |
MGAWN1;MGAWN1 |
23 |
Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration |
Completed |
NCT00381433 |
Phase 1 |
AVI-4065 Injection |
24 |
Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine |
Completed |
NCT03055000 |
Phase 1 |
|
25 |
An Exploratory Study of the Safety, Tolerability, Pharmacokinetics and Potential Effectiveness of AVI-4020 Injection in Patients Presenting With Presumptive Acute Neuroinvasive West Nile Virus (WNV) Disease |
Terminated |
NCT00091845 |
Phase 1 |
AVI-4020 Injection |
26 |
Assessment of the Impact of Notification of Blood Donors Testing Positive for Microbiology Markers: What is the Psychological Impact of Notification and Does the Method of Notification Influence the Outcome? |
Unknown status |
NCT01050881 |
|
|
27 |
Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease |
Completed |
NCT00069303 |
|
|
28 |
Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease |
Completed |
NCT00138463 |
|
|
29 |
Surveillance of Summer Febrile Syndromes of Viral Origin in South of France |
Completed |
NCT00842166 |
|
|
30 |
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases |
Completed |
NCT00068926 |
|
|
31 |
Retrovirus Epidemiology Donor Study-II (REDS-II) |
Completed |
NCT00097006 |
|
|
32 |
Pilot Study to Detect DENGUE Virus in Sperm. |
Completed |
NCT03612609 |
|
|
33 |
Organ Transplant Infection Prevention and Detection Project 1.0; Cohort Study of Transplant Recipients at "Ultra-High" Risk for Invasive Fungal Infections |
Completed |
NCT00177801 |
|
|
34 |
Clinical Evaluation of the FilmArray® Global Fever (GF) Panel |
Recruiting |
NCT02968355 |
|
|
35 |
Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r |
Recruiting |
NCT01099852 |
|
|
36 |
Autologous Ovarian Tissue Transplantation |
Recruiting |
NCT03496636 |
|
|
37 |
The Collection and Storage of Umbilical Cord Blood for Transplantation |
Recruiting |
NCT01728545 |
|
|
38 |
The Threat of Infectious Encephalitis in Southeast Asia: SouthEast Asia Encephalitis Project |
Active, not recruiting |
NCT04089436 |
|
|
39 |
Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols |
Enrolling by invitation |
NCT00068003 |
|
|
40 |
Prospective Investigation of Oxidative Stress in West Nile Virus Infection |
Not yet recruiting |
NCT04371003 |
|
|
41 |
Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus |
No longer available |
NCT01206504 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|